Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

smartpatient

- PMLiVE

Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

The companies will aim to discover and develop new therapeutics for the group of disorders

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

Novartis to expand renal disease pipeline with $1.7bn Regulus acquisition

The agreement includes a candidate for autosomal dominant polycystic kidney disease

- PMLiVE

Novartis to invest $23bn into US-based infrastructure over next five years

The commitment will allow the company to produce 100% of its key medicines end-to-end in the US

- PMLiVE

Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy

Almost 13 out of every million people in the US are diagnosed with IgAN each year

- PMLiVE

Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

The authorisation approximately triples the number of patients eligible to receive the therapy

- PMLiVE

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

- PMLiVE

Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy

The company said it is planning to file regulatory applications for OAV101 IT this year

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

- PMLiVE

Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

- PMLiVE

Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition

The deal includes a candidate in phase 3 development to prevent complications of atrial fibrillation

- PMLiVE

Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

The drug is already approved in the UK to treat advanced cases of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links